Skip to Main Content
Page banner

Submitted
Being Assessed
In review
Responded
Thanks for your vote
This voting milestone has now ended, and the idea has progressed to a private milestone
Return to idea list
Thanks for approving the idea
This milestone has now ended, and the idea has progressed to a private milestone
Return to idea list

Developing an aptamer binder selective for the spike protein in SARS Cov-2 which we expect to complete in 3-4 weeks submitted by Peter Cousins

B: One to watch

We’ve started a project to develop an aptamer binder selective for the spike protein in SARS Cov-2 which we expect to complete in 3-4 weeks. 

Our aim is to work this into a point-of-care test for the SARS Cov-2 virus detection in saliva samples in 10 minutes, omitting the need for lab-based PCR testing for the virus, massively scaling up the number of virus tests that can be conducted.

We plan to have a proof-of-concept device ready to scale up in two months.

This isn't a  PCR method, but is alternative method to give you the same result.

 

Not yet validated, but we hope to deploy in 3 months, once we have an aptamer binder.

 

Production volume is same as  for regular lateral flow tests - millions. And at a low cost  per test.

 

No risks or barriers - LFD scale up and production is a well trodden path. The scale up the SARS Cov-2 aptamer binder is straightforward, as this in oligo sequence, and as such can be synthesised at scale by a number of companies.

 

 We are looking for partners to scale up the LFD and maufacture it. 

edited on Jul 7, 2020 by Tom Jordan
You will need to login to post a comment

Bev Matthews Apr 22, 2020

Status label added: B

Reply 0

Tom Jordan Jun 27, 2020

Update:

Hi Tom

Thanks for your email. Your timing is good. We are about to start a 4 week lateral flow development project for a point-of-care test in saliva, based on our SARS CoV-2 spike S1 aptamer binder.

The aptamer is very high affinity, with a KD of in the picomolar region (see attached – feel free to share this). We believe the COVID19 antigen LFD we are building based on this will have a very low limit of detection and has every chance of clinically useful point-of-care test.

We are looking to clinically validate at the end of July with saliva specimens, so if anyone in the network has access to these we’d be delighted to speak with them.

Best regards

Peter

Reply 0

Tom Jordan Jul 7, 2020

The idea has been progressed to the next milestone.

Reply 0

Share